Your browser doesn't support javascript.
loading
Montrer: 20 | 50 | 100
Résultats 1 - 1 de 1
Filtre
Ajouter des filtres








Gamme d'année
1.
Clinics ; 72(4): 231-237, Apr. 2017. tab, graf
Article Dans Anglais | LILACS | ID: biblio-840064

Résumé

OBJECTIVES: The present study was designed to evaluate the bone phenotypes and mechanisms involved in bone disorders associated with hepatic osteodystrophy. Hepatocellular disease was induced by carbon tetrachloride (CCl4). In addition, the effects of disodium pamidronate on bone tissue were evaluated. METHODS: The study included 4 groups of 15 mice: a) C = mice subjected to vehicle injections; b) C+P = mice subjected to vehicle and pamidronate injections; c) CCl4+V = mice subjected to CCl4 and vehicle injections; and d) CCl4+P = mice subjected to CCl4 and pamidronate injections. CCl4 or vehicle was administered for 8 weeks, while pamidronate or vehicle was injected at the end of the fourth week. Bone histomorphometry and biomechanical analysis were performed in tibiae, while femora were used for micro-computed tomography and gene expression. RESULTS: CCl4 mice exhibited decreased bone volume/trabecular volume and trabecular numbers, as well as increased trabecular separation, as determined by bone histomorphometry and micro-computed tomography, but these changes were not detected in the group treated with pamidronate. CCl4 mice showed increased numbers of osteoclasts and resorption surface. High serum levels of receptor activator of nuclear factor-κB ligand and the increased expression of tartrate-resistant acid phosphatase in the bones of CCl4 mice supported the enhancement of bone resorption in these mice. CONCLUSION: Taken together, these results suggest that bone resorption is the main mechanism of bone loss in chronic hepatocellular disease in mice.


Sujets)
Animaux , Mâle , Maladies osseuses métaboliques/étiologie , Maladies osseuses métaboliques/traitement médicamenteux , Remodelage osseux/effets des médicaments et des substances chimiques , Diphosphonates/pharmacologie , Agents de maintien de la densité osseuse/pharmacologie , Maladies du foie/complications , Phosphore/administration et posologie , Os et tissu osseux/effets des médicaments et des substances chimiques , Os et tissu osseux/métabolisme , Os et tissu osseux/imagerie diagnostique , Maladies osseuses métaboliques/métabolisme , Résorption osseuse/métabolisme , Tétrachloro-méthane , Modèles animaux de maladie humaine , Sous-unité alpha 1 du facteur CBF/génétique , Ligand de RANK/génétique , Ostéoprotégérine/génétique , Microtomographie aux rayons X , Tartrate-resistant acid phosphatase/génétique , Cirrhose du foie/induit chimiquement , Cirrhose du foie/métabolisme , Maladies du foie/métabolisme , Souris de lignée C57BL
SÉLECTION CITATIONS
Détails de la recherche